Lichtenberger 2019 Cancer Res
| Lichtenberger LM, Vijayan KV (2019) Are platelets the primary target of aspirin's remarkable anticancer activity? Cancer Res 79:3820-3. https://doi.org/10.1158/0008-5472.CAN-19-0762 |
Lichtenberger LM, Vijayan KV (2019) Cancer Res
Abstract: Aspirin, when administered at low doses, has emerged as a powerful anticancer drug due to both chemopreventive activity against many forms of cancer and its ability to block metastases when administered postdiagnosis. Platelets, which are often elevated in circulation during the latter stages of cancer, are known to promote epithelial-mesenchymal transition, cancer cell growth, survival in circulation, and angiogenesis at sites of metastases. Low-dose aspirin has been demonstrated to block this procarcinogenic action of platelets. In this article, we present evidence that aspirin's unique ability to irreversibly inhibit platelet cyclooxygenase-1 is a key mechanism by which aspirin exerts anticancer activity.
• Bioblast editor: Gnaiger E
Labels: MiParea: Pharmacology;toxicology
Pathology: Cancer
Organism: Human Tissue;cell: Platelet
Aspirin
